This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Treatment of Subclinical Hyperthyroidism

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2007 by University Hospital, Strasbourg, France.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
University Hospital, Strasbourg, France Identifier:
First received: September 13, 2005
Last updated: April 19, 2012
Last verified: November 2007
Objective: To determine if the treatment of subclinical hyperthyroidism will reduce the rate of atrial fibrillation, the main complication of this condition.

Condition Phase
Subclinical Hyperthyroidism Atrial Fibrillation Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Place de l'Iode RadioActif Dans l'HyperThyroïdiE Sub-clinique (PIRHATES)/ Evaluation of the Interest of Subclinical Hyperthyroidism Treatment

Resource links provided by NLM:

Further study details as provided by University Hospital, Strasbourg, France:

Biospecimen Retention:   Samples Without DNA

Estimated Enrollment: 300
Study Start Date: August 2005
Detailed Description:
Randomized open-labelled multicentre study comparing radioiodine vs medical supervision without treatment

Ages Eligible for Study:   50 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
patients referred to tertiary hospitals for advice on thyroïd disease

Inclusion Criteria:

  • Men and women aged 50 and greater
  • Isolated decreased thyroid-stimulating hormone (TSH) with normal FT4 and FT3 levels

Exclusion Criteria:

  • Iodide overload
  • Non sinusal heart rhythm
  • Severe heart disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00213720

Contact: Bernard Goichot, MD 333 88 12 75 93

Patrick Roger Recruiting
Bordeaux, France
Contact: Patrick Roger, MD    335 57 65 64 33   
Philippe Thiéblot Not yet recruiting
Clermont-Ferrand, France
Contact: Philippe Thiéblot, MD    334 73 75 15 33   
Jean-Marcel Brun Not yet recruiting
Dijon, France
Contact: Jean-Marcel Brun    333 80 29 34 53   
Jean-Louis Wemeau Recruiting
Lille, France
Contact: Jean-Louis Wemeau, MD    333 20 44 41 18   
Marie-Pierre Teissier Recruiting
Limoges, France
Contact: Marie-Pierre Teissier, MD    335 55 05 68 51   
Jacques Orgiazzi Recruiting
Lyon, France
Contact: Jacques Orgiazzi, MD    334 78 86 14 88   
Bernard Conte-Delvox Not yet recruiting
Marseille, France
Contact: Bernard Conte-Delvox, MD    334 91 38 65 97   
CH de Montbrison Recruiting
Montbrison, France, 42605
Contact: Luc Millot, MD    0033477967853   
Principal Investigator: Luc Millot, MD         
Jacques Bringer Not yet recruiting
Montpellier, France
Contact: Jacques Bringer    334 67 33 83 82   
Marc Klein Recruiting
Nancy, France
Contact: Marc Klein    333 83 15 34 31   
Michel Rodier Recruiting
Nimes, France
Contact: Michel Rodier, MD    334 66 68 33 21   
Laurence Leenhardt Recruiting
Paris, France
Contact: Laurence Leenhardt, MD    331 42 17 62 81   
Richard Marechaud Recruiting
Poitiers, France
Contact: Richard Marechaud    335 49 44 43 80   
Brigitte Delemer Recruiting
Reims, France
Contact: Brigitte Delemer, MD    333 26 78 75 33 / 79 42   
Claire Schvartz Recruiting
Reims, France
Contact: Claire Schvartz, MD    333 26 50 43 21   
Sub-Investigator: Béatrice Maes, MD         
Sub-Investigator: Jean-Marie Pochart, MD         
Didier Maugendre Not yet recruiting
Rennes, France
Contact: Didier Maugendre, MD    332 99 26 71 42   
Jean-Marc Kuhn Recruiting
Rouen, France
Contact: Jean-Marc Kuhn, MD    332 32 88 90 82   
Bruno Estour Recruiting
Saint-Etienne, France
Contact: Bruno Estour, MD    334 77 12 77 27   
Sub-Investigator: Luc Millot, MD         
Centre Paul Strauss Recruiting
Strasbourg, France, 67000
Contact: Olivier Schneegans, MD    0033388252428   
Principal Investigator: Olivier Schneegans, MD         
Hopitaux Universitaires de Strasbourg Recruiting
Strasbourg, France
Contact: Bernard Goichot, MD    333 88 12 75 93   
Sub-Investigator: Jean-Louis Schlienger, MD         
Sub-Investigator: Fabienne Grunenberger, MD         
Sub-Investigator: Alain Pradignac, MD         
Sub-Investigator: Stephane Vinzio, MD         
Philippe Caron Recruiting
Toulouse, France
Contact: Philippe Caron         
Pierre Lecomte Recruiting
Tours, France
Contact: Pierre Lecomte, MD    332 47 47 87.03   
Sponsors and Collaborators
University Hospital, Strasbourg, France
Principal Investigator: Bernard Goichot, MD Hopitaux Universitaires de Strasbourg
  More Information

Responsible Party: University Hospital, Strasbourg, France Identifier: NCT00213720     History of Changes
Other Study ID Numbers: 3463
Study First Received: September 13, 2005
Last Updated: April 19, 2012

Keywords provided by University Hospital, Strasbourg, France:
atrial fibrillation
quality of life
radioiodine treatment

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Thyroid Diseases
Endocrine System Diseases processed this record on August 23, 2017